Streetbeat News

Products Services

HLVX

HilleVax and Kangh have entered into an exclusive license agreement for the development and commercialization of a hexavalent VLP norovirus vaccine candidate outside of China. This partnership could potentially enhance HilleVax's product pipeline and market reach, while providing Kangh with licensing revenues and a share in the global market, excluding China.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm

NRIX

Nurix Therapeutics has announced its key objectives and anticipated milestones for the year 2024. The company is expected to provide updates on its progress and achievements throughout the year, which may include clinical trial results, regulatory filings, partnerships, or other significant developments. Investors will be closely monitoring Nurix's progress towards these goals as they can have a substantial impact on the company's performance and stock valuation.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:11 pm

TVTX

Travere Therapeutics reported receiving 459 new patient start forms for Filspari (Sparsentan) in Q4 2023. Preliminary net product sales for Filspari reached $15M in Q4 and totaled $30M since its commercial launch in February 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:10 pm

CABA

Cabaletta Bio has received additional FDA Fast Track Designations for its investigational drug CABA-201, aimed at treating dermatomyositis and systemic sclerosis. The company has previously obtained FDA clearance for IND applications for CABA-201 in various autoimmune conditions such as SLE, myositis, SSc, and gMG.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:05 pm

HARP

MRK

Merck & Co Inc (NYSE:MRK) is in talks to acquire Harpoon Therapeutics Inc (NASDAQ:HARP) for an estimated $700 million, at a proposed price of around $23 per share. This acquisition is part of Merck's strategy to diversify its oncology portfolio beyond its top-selling drug Keytruda. Harpoon's lead candidate, HPN328, has shown promising results in early-stage trials for small-cell lung cancer. MRK's stock closed at $117.20, while HARP's shares surged 99.8% to $21.08 in premarket trading.

Portfolio Pulse from Vandana Singh

January 08, 2024 | 12:04 pm

CROX

Crocs Inc. forecasts a revenue growth of 3% to 5% for 2024 over 2023, with the Crocs brand expected to grow 4% to 6% and the HEYDUDE brand projected to be flat to slightly up.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:04 pm

CEVA

Ceva, Inc. (NASDAQ:CEVA) has expanded its AI ecosystem for the NeuPro-M NPU IP by forming partnerships with Visionary.ai and ENOT.ai, targeting automotive and Edge AI applications. Visionary.ai enhances camera capabilities in low-light and HDR scenarios, while ENOT.ai's role in the partnership was not detailed in the article.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:03 pm

AAPL

Jefferies research note predicts further declines in Apple Inc.'s (AAPL) iPhone sales in China, despite new releases. Sales dropped 30% year-on-year and are expected to continue falling into 2024. Discounts haven't led to volume growth, and Apple's market share is affected by Huawei's resurgence with its Mate 60 Pro. The U.S. sanctions have led Huawei to develop its own software ecosystem. Apple's sales are also impacted by China's ban on Apple devices for state-backed firms and government departments, contributing to the sales decline.

Portfolio Pulse from Ananya Gairola

January 08, 2024 | 11:54 am

ASXC

Asensus Surgical expects FY23 unaudited revenue of $8.2M-$8.8M, surpassing the consensus estimate of $7.79M. Q4 sales are projected to be $5.1M-$5.7M, also above the consensus of $4.67M. The company reported a 14% increase in global procedures to over 3,550 for the year and initiated eight Senhance Surgical Programs. As of December 31, 2023, Asensus had about $21.0 million in cash and short-term investments. In Q4, over 835 procedures were performed, and five new Senhance Programs were launched in various regions including Germany, Romania, the CIS region, and Japan.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:52 am

CMC

Commercial Metals Company (CMC) anticipates a robust construction season in spring and summer, driven by increased infrastructure investments. This is expected to bolster strong demand in North America Steel and Emerging Businesses beyond Q2.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:52 am